HiFiBiO raises series D funds to advance immuno-oncology candidates
HiFiBiO Therapeutics plans to accelerate two immuno-oncology programmes and to validate its Drug Intelligent Science platform in clinical trials.
Immunology
UK CMA launches inquiry into $39bn AstraZeneca and Alexion merger
The UK Competition and Markets Authority started enquiring into the AstraZeneca proposed Alexion acquisition for...
Exscientia signs $1.2bn AI drug discovery deal with BMS
Bristol-Myers Squibb and Exscientia enter a partnership agreement to discover small molecule drug candidates using...
ViiV Healthcare starts rolling submission of cabotegravir for HIV prevention
ViiV Healthcare has begun a rolling submission of a new drug application (NDA) with the...
There is not enough evidence to blame India’s second wave of COVID-19 on mutations
Despite the alarming spike in new cases with India’s second wave, there is simply not...
AstraZeneca gets US clearance for proposed Alexion acquisition
The US Federal Trade Commission (FTC) has granted clearance to AstraZeneca for its proposed acquisition of Alexion Pharmaceuticals for approximately $39bn or $175 a share. The latest development comes after…
Sanofi acquires biotech company Tidal Therapeutics for $470m
Sanofi has acquired biotech company Tidal Therapeutics to add an advanced mRNA-based research platform with applications in various disease areas to its portfolio in a deal totalling approximately $470m. According…
Amgen signs agreement to acquire Rodeo Therapeutics for $721m
Amgen has entered an agreement to acquire US-based biopharmaceutical company Rodeo Therapeutics for up to $721m. According to the deal, Amgen will acquire all outstanding shares of Rodeo for an…
UCB and Microsoft expand drug development partnership
UCB and Microsoft have entered into a new multi-year, strategic collaboration. The collaboration will merge Microsoft’s computational services, Cloud and artificial intelligence (AI) with UCB’s drug discovery and development capabilities.…
Lilly, Rigel enter $960m deal to develop RIPK1 inhibitors
Eli Lilly and Company and Rigel Pharmaceuticals have entered into a global exclusive license agreement and strategic collaboration to co-develop and commercialise the latter’s receptor-interacting serine / threonine-protein kinase 1…
AstraZeneca to acquire biopharmaceutical firm Alexion for $39bn
AstraZeneca has signed a definitive agreement to acquire global biopharmaceutical company Alexion Pharmaceuticals for $39bn or $175 a share. According to the agreement, Alexion shareholders will receive $60 in cash…
